This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaye, D. M. Articles by Esler, M. D. Search for Related Content PubMed PubMed Citation Articles by Kaye, D. M. Articles by Esler, M. D.

Antiadrenergic effect of chronic amiodarone therapy in human heart failure

^a Alfred Baker Medical Unit, Baker Medical Research Institute, Melbourne, Australia

View larger version (16K): [in a new window]   Figure 1 Bar graphs representing the differences in cardiac spillover rates for norepinephrine (NE SR), dihydroxyphenylalanine (DOPA SR), dihydroxyphenylglycol (DHPG SR) and tritium-labeled dihydroxyphenylglycol (3H DHPG SR), for patients not treated with amiodarone (A–) and those treated with amiodarone (A+). *p < 0.05, **p < 0.01, ***p < 0.001.

View larger version (10K): [in a new window]   Figure 2 Bar graph comparing the ratios of transcardiac spillover rates for dihydroxyphenylalanine to norepinephrine (DOPA:NE SR), dihydroxyphenylglycol to norepinephrine (DHPG:NE SR) and tritium-labeled dihydroxyphenylglycol to norepinephrine (3H DHPG:NE SR) for nontreated (A–) and treated patients (A+). **p < 0.05.